Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study. Read more about Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study.
Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells. Read more about Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells.
Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy. Read more about Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy.
Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. Read more about Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma.
Menopausal hormone therapy and breast cancer: what is the true size of the increased risk? Read more about Menopausal hormone therapy and breast cancer: what is the true size of the increased risk?
Nut consumption and prostate cancer risk and mortality. Read more about Nut consumption and prostate cancer risk and mortality.
Pre-diagnostic circulating sex hormone levels and risk of prostate cancer by ERG tumour protein expression. Read more about Pre-diagnostic circulating sex hormone levels and risk of prostate cancer by ERG tumour protein expression.
Histopathological features of papillary thyroid carcinomas detected during four screening examinations of a Ukrainian-American cohort. Read more about Histopathological features of papillary thyroid carcinomas detected during four screening examinations of a Ukrainian-American cohort.
The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial. Read more about The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial.
Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma. Read more about Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma.
